Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial
Identifieur interne : 002056 ( Istex/Corpus ); précédent : 002055; suivant : 002057Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial
Auteurs : William Ondo ; Christine Hunter ; Kevin Dat Vuong ; Kenneth Schwartz ; Joseph JankovicSource :
- Movement Disorders [ 0885-3185 ] ; 2000-07.
English descriptors
- KwdEn :
Abstract
Essential tremor (ET) is a common movement disorder that often becomes refractory to conventional pharmacologic management. Open‐label studies suggest that gabapentin is efficacious for ET, but the results of controlled trials have been mixed. To determine the efficacy and tolerability of gabapentin in ET, we conducted a double‐blind, placebo‐controlled, cross‐over trial evaluating two doses (1800 mg per day and 3600 mg per day; N = 25). Patients on other ET medications were maintained on their concurrent medications for 3 months prior to study initiation and throughout the study. Twenty patients (mean age, 69.9 ± 6.1 yrs) completed the study. Overall, patient global assessments (p <0.05), observed tremor scores (p <0.005), water pouring scores (p <0.05), and activities of daily living scores (p <0.005) significantly improved. Accelerometry scores, spirographs, and investigator global impression scores did not improve. The results were similar for high and low doses. Statistical regression models did not demonstrate any significant predictors for response. Gabapentin may be effective in some cases of ET.
Url:
DOI: 10.1002/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0
Links to Exploration step
ISTEX:834F3FB52302D7533ECA27BFB9A31F46CEA1F0EDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial</title><author><name sortKey="Ondo, William" sort="Ondo, William" uniqKey="Ondo W" first="William" last="Ondo">William Ondo</name><affiliation><mods:affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name><affiliation><mods:affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Vuong, Kevin Dat" sort="Vuong, Kevin Dat" uniqKey="Vuong K" first="Kevin Dat" last="Vuong">Kevin Dat Vuong</name><affiliation><mods:affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Schwartz, Kenneth" sort="Schwartz, Kenneth" uniqKey="Schwartz K" first="Kenneth" last="Schwartz">Kenneth Schwartz</name><affiliation><mods:affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><mods:affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:834F3FB52302D7533ECA27BFB9A31F46CEA1F0ED</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1002/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0</idno><idno type="url">https://api.istex.fr/document/834F3FB52302D7533ECA27BFB9A31F46CEA1F0ED/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002056</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial</title><author><name sortKey="Ondo, William" sort="Ondo, William" uniqKey="Ondo W" first="William" last="Ondo">William Ondo</name><affiliation><mods:affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name><affiliation><mods:affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Vuong, Kevin Dat" sort="Vuong, Kevin Dat" uniqKey="Vuong K" first="Kevin Dat" last="Vuong">Kevin Dat Vuong</name><affiliation><mods:affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Schwartz, Kenneth" sort="Schwartz, Kenneth" uniqKey="Schwartz K" first="Kenneth" last="Schwartz">Kenneth Schwartz</name><affiliation><mods:affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><mods:affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-07">2000-07</date><biblScope unit="vol">15</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="678">678</biblScope><biblScope unit="page" to="682">682</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">834F3FB52302D7533ECA27BFB9A31F46CEA1F0ED</idno><idno type="DOI">10.1002/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0</idno><idno type="ArticleID">MDS1012</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Accelerometry</term><term>Essential tremor</term><term>Gabapentin</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="fr">Essential tremor (ET) is a common movement disorder that often becomes refractory to conventional pharmacologic management. Open‐label studies suggest that gabapentin is efficacious for ET, but the results of controlled trials have been mixed. To determine the efficacy and tolerability of gabapentin in ET, we conducted a double‐blind, placebo‐controlled, cross‐over trial evaluating two doses (1800 mg per day and 3600 mg per day; N = 25). Patients on other ET medications were maintained on their concurrent medications for 3 months prior to study initiation and throughout the study. Twenty patients (mean age, 69.9 ± 6.1 yrs) completed the study. Overall, patient global assessments (p <0.05), observed tremor scores (p <0.005), water pouring scores (p <0.05), and activities of daily living scores (p <0.005) significantly improved. Accelerometry scores, spirographs, and investigator global impression scores did not improve. The results were similar for high and low doses. Statistical regression models did not demonstrate any significant predictors for response. Gabapentin may be effective in some cases of ET.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>William Ondo MD</name><affiliations><json:string>Baylor College of Medicine, Houston, Texas, U.S.A.</json:string></affiliations></json:item><json:item><name>Christine Hunter RN</name><affiliations><json:string>Baylor College of Medicine, Houston, Texas, U.S.A.</json:string></affiliations></json:item><json:item><name>Kevin Dat Vuong MA</name><affiliations><json:string>Baylor College of Medicine, Houston, Texas, U.S.A.</json:string></affiliations></json:item><json:item><name>Kenneth Schwartz PA</name><affiliations><json:string>Baylor College of Medicine, Houston, Texas, U.S.A.</json:string></affiliations></json:item><json:item><name>Joseph Jankovic MD</name><affiliations><json:string>Baylor College of Medicine, Houston, Texas, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Essential tremor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Gabapentin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Accelerometry</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Essential tremor (ET) is a common movement disorder that often becomes refractory to conventional pharmacologic management. Open‐label studies suggest that gabapentin is efficacious for ET, but the results of controlled trials have been mixed. To determine the efficacy and tolerability of gabapentin in ET, we conducted a double‐blind, placebo‐controlled, cross‐over trial evaluating two doses (1800 mg per day and 3600 mg per day; N = 25). Patients on other ET medications were maintained on their concurrent medications for 3 months prior to study initiation and throughout the study. Twenty patients (mean age, 69.9 ± 6.1 yrs) completed the study. Overall, patient global assessments (p >0.05), observed tremor scores (p >0.005), water pouring scores (p >0.05), and activities of daily living scores (p >0.005) significantly improved. Accelerometry scores, spirographs, and investigator global impression scores did not improve. The results were similar for high and low doses. Statistical regression models did not demonstrate any significant predictors for response. Gabapentin may be effective in some cases of ET.</abstract><qualityIndicators><score>5.172</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1121</abstractCharCount><pdfWordCount>3192</pdfWordCount><pdfCharCount>20409</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>165</abstractWordCount></qualityIndicators><title>Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial</title><genre><json:string>Serial article</json:string></genre><host><volume>15</volume><pages><total>5</total><last>682</last><first>678</first></pages><issn><json:string>0885-3185</json:string></issn><issue>4</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1002/1531-8257(200007)15:4>678::AID-MDS1012>3.0.CO;2-0</json:string></doi><id>834F3FB52302D7533ECA27BFB9A31F46CEA1F0ED</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/834F3FB52302D7533ECA27BFB9A31F46CEA1F0ED/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/834F3FB52302D7533ECA27BFB9A31F46CEA1F0ED/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/834F3FB52302D7533ECA27BFB9A31F46CEA1F0ED/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>John Wiley & Sons, Inc.</p></availability><date>2000</date></publicationStmt><notesStmt><note>Parke‐Davis Pharmaceuticals</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial</title><author><persName><forename type="first">William</forename><surname>Ondo</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: 6550 Fannin Dr, Suite 1801, Houston, TX 77030, U.S.A.</p></note><affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation></author><author><persName><forename type="first">Christine</forename><surname>Hunter</surname><roleName type="degree">RN</roleName></persName><affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation></author><author><persName><forename type="first">Kevin Dat</forename><surname>Vuong</surname><roleName type="degree">MA</roleName></persName><affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation></author><author><persName><forename type="first">Kenneth</forename><surname>Schwartz</surname><roleName type="degree">PA</roleName></persName><affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation></author><author><persName><forename type="first">Joseph</forename><surname>Jankovic</surname><roleName type="degree">MD</roleName></persName><affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-07"></date><biblScope unit="vol">15</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="678">678</biblScope><biblScope unit="page" to="682">682</biblScope></imprint></monogr><idno type="istex">834F3FB52302D7533ECA27BFB9A31F46CEA1F0ED</idno><idno type="DOI">10.1002/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0</idno><idno type="ArticleID">MDS1012</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="fr"><p>Essential tremor (ET) is a common movement disorder that often becomes refractory to conventional pharmacologic management. Open‐label studies suggest that gabapentin is efficacious for ET, but the results of controlled trials have been mixed. To determine the efficacy and tolerability of gabapentin in ET, we conducted a double‐blind, placebo‐controlled, cross‐over trial evaluating two doses (1800 mg per day and 3600 mg per day; N = 25). Patients on other ET medications were maintained on their concurrent medications for 3 months prior to study initiation and throughout the study. Twenty patients (mean age, 69.9 ± 6.1 yrs) completed the study. Overall, patient global assessments (p <0.05), observed tremor scores (p <0.005), water pouring scores (p <0.05), and activities of daily living scores (p <0.005) significantly improved. Accelerometry scores, spirographs, and investigator global impression scores did not improve. The results were similar for high and low doses. Statistical regression models did not demonstrate any significant predictors for response. Gabapentin may be effective in some cases of ET.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Essential tremor</term></item><item><term>Gabapentin</term></item><item><term>Accelerometry</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1999-10-12">Received</change><change when="2000-04-11">Registration</change><change when="2000-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/834F3FB52302D7533ECA27BFB9A31F46CEA1F0ED/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/1531-8257(200007)15:4<>1.0.CO;2-Z</doi><numberingGroup><numbering type="journalVolume" number="15">15</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="2000-07">July 2000</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="12" status="forIssue"><doi origin="wiley" registered="yes">10.1002/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0</doi><idGroup><id type="unit" value="MDS1012"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2000 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1999-10-12"></event><event type="manuscriptRevised" date="2000-03-22"></event><event type="manuscriptAccepted" date="2000-04-11"></event><event type="firstOnline" date="2001-01-31"></event><event type="publishedOnlineFinalForm" date="2001-01-31"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">678</numbering><numbering type="pageLast">682</numbering></numberingGroup><correspondenceTo>6550 Fannin Dr, Suite 1801, Houston, TX 77030, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1012.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="40"></count><count type="wordTotal" number="3015"></count></countGroup><titleGroup><title type="main" xml:lang="en">Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial</title><title type="short" xml:lang="en">Gabapentin for ET</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>William</givenNames><familyName>Ondo</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Christine</givenNames><familyName>Hunter</familyName><degrees>RN</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Kevin Dat</givenNames><familyName>Vuong</familyName><degrees>MA</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Kenneth</givenNames><familyName>Schwartz</familyName><degrees>PA</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Joseph</givenNames><familyName>Jankovic</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Essential tremor</keyword><keyword xml:id="kwd2">Gabapentin</keyword><keyword xml:id="kwd3">Accelerometry</keyword></keywordGroup><fundingInfo><fundingAgency>Parke‐Davis Pharmaceuticals</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="fr"><title type="main">Abstract</title><p>Essential tremor (ET) is a common movement disorder that often becomes refractory to conventional pharmacologic management. Open‐label studies suggest that gabapentin is efficacious for ET, but the results of controlled trials have been mixed. To determine the efficacy and tolerability of gabapentin in ET, we conducted a double‐blind, placebo‐controlled, cross‐over trial evaluating two doses (1800 mg per day and 3600 mg per day; N = 25). Patients on other ET medications were maintained on their concurrent medications for 3 months prior to study initiation and throughout the study. Twenty patients (mean age, 69.9 ± 6.1 yrs) completed the study. Overall, patient global assessments (p <0.05), observed tremor scores (p <0.005), water pouring scores (p <0.05), and activities of daily living scores (p <0.005) significantly improved. Accelerometry scores, spirographs, and investigator global impression scores did not improve. The results were similar for high and low doses. Statistical regression models did not demonstrate any significant predictors for response. Gabapentin may be effective in some cases of ET.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Gabapentin for ET</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial</title></titleInfo><name type="personal"><namePart type="given">William</namePart><namePart type="family">Ondo</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation><description>Correspondence: 6550 Fannin Dr, Suite 1801, Houston, TX 77030, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Hunter</namePart><namePart type="termsOfAddress">RN</namePart><affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kevin Dat</namePart><namePart type="family">Vuong</namePart><namePart type="termsOfAddress">MA</namePart><affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kenneth</namePart><namePart type="family">Schwartz</namePart><namePart type="termsOfAddress">PA</namePart><affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joseph</namePart><namePart type="family">Jankovic</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2000-07</dateIssued><dateCaptured encoding="w3cdtf">1999-10-12</dateCaptured><dateValid encoding="w3cdtf">2000-04-11</dateValid><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">40</extent><extent unit="words">3015</extent></physicalDescription><abstract lang="fr">Essential tremor (ET) is a common movement disorder that often becomes refractory to conventional pharmacologic management. Open‐label studies suggest that gabapentin is efficacious for ET, but the results of controlled trials have been mixed. To determine the efficacy and tolerability of gabapentin in ET, we conducted a double‐blind, placebo‐controlled, cross‐over trial evaluating two doses (1800 mg per day and 3600 mg per day; N = 25). Patients on other ET medications were maintained on their concurrent medications for 3 months prior to study initiation and throughout the study. Twenty patients (mean age, 69.9 ± 6.1 yrs) completed the study. Overall, patient global assessments (p <0.05), observed tremor scores (p <0.005), water pouring scores (p <0.05), and activities of daily living scores (p <0.005) significantly improved. Accelerometry scores, spirographs, and investigator global impression scores did not improve. The results were similar for high and low doses. Statistical regression models did not demonstrate any significant predictors for response. Gabapentin may be effective in some cases of ET.</abstract><note type="funding">Parke‐Davis Pharmaceuticals</note><subject lang="en"><genre>Keywords</genre><topic>Essential tremor</topic><topic>Gabapentin</topic><topic>Accelerometry</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>678</start><end>682</end><total>5</total></extent></part></relatedItem><identifier type="istex">834F3FB52302D7533ECA27BFB9A31F46CEA1F0ED</identifier><identifier type="DOI">10.1002/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0</identifier><identifier type="ArticleID">MDS1012</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2000 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>John Wiley & Sons, Inc.</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002056 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002056 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:834F3FB52302D7533ECA27BFB9A31F46CEA1F0ED
|texte= Gabapentin for essential tremor: A multiple‐dose, double‐blind, placebo‐controlled trial
}}
| This area was generated with Dilib version V0.6.23. |  |